ZIVO Bioscience announces shareholder letter availability; company plans SEC deregistration and public reporting halt

Reuters03-28

ZIVO Bioscience announces shareholder letter availability; company plans SEC deregistration and public reporting halt

Zivo Bioscience said a letter to shareholders from Chairman, President and CEO John B. Payne is available and outlines plans to deregister its securities with the SEC and stop public reporting.
The letter cites public-company compliance costs and shareholder dilution from capital raises to fund reporting expenses as reasons for the decision.
It states the company expects meaningful revenue from its AgTech product line through a distribution relationship in the coming months and says lower operating costs could support positive cash flow.
Payne said animal health companies are conducting due diligence on Zivo’s non-antibiotic immune-modulating technology and that The University of Georgia plans to use Zivo’s product in avian influenza studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zivo Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603271643BIZWIRE_USPR_____20260327_BW190358) on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622580804?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-28 04:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622580804","market":"fut","top_or_hot":-1,"title":"ZIVO Bioscience announces shareholder letter availability; company plans SEC deregistration and public reporting halt","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ZIVO Bioscience announces shareholder letter availability; company plans SEC deregistration and public reporting halt\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          <a href=\"https://laohu8.com/S/ZIVO\">Zivo Bioscience</a> said a letter to shareholders from Chairman, President and CEO John B. Payne is available and outlines plans to deregister its securities with the SEC and stop public reporting.\n        </li>\n<li>\n          The letter cites public-company compliance costs and shareholder dilution from capital raises to fund reporting expenses as reasons for the decision.\n        </li>\n<li>\n          It states the company expects meaningful revenue from its AgTech product line through a distribution relationship in the coming months and says lower operating costs could support positive cash flow.\n        </li>\n<li>\n          Payne said animal health companies are conducting due diligence on Zivo’s non-antibiotic immune-modulating technology and that The University of Georgia plans to use Zivo’s product in avian influenza studies.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ZIVOW\">Zivo Bioscience</a> Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603271643BIZWIRE_USPR_____20260327_BW190358) on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ZIVO Bioscience announces shareholder letter availability; company plans SEC deregistration and public reporting halt</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZIVO Bioscience announces shareholder letter availability; company plans SEC deregistration and public reporting halt\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-28 04:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ZIVO Bioscience announces shareholder letter availability; company plans SEC deregistration and public reporting halt\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          <a href=\"https://laohu8.com/S/ZIVO\">Zivo Bioscience</a> said a letter to shareholders from Chairman, President and CEO John B. Payne is available and outlines plans to deregister its securities with the SEC and stop public reporting.\n        </li>\n<li>\n          The letter cites public-company compliance costs and shareholder dilution from capital raises to fund reporting expenses as reasons for the decision.\n        </li>\n<li>\n          It states the company expects meaningful revenue from its AgTech product line through a distribution relationship in the coming months and says lower operating costs could support positive cash flow.\n        </li>\n<li>\n          Payne said animal health companies are conducting due diligence on Zivo’s non-antibiotic immune-modulating technology and that The University of Georgia plans to use Zivo’s product in avian influenza studies.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ZIVOW\">Zivo Bioscience</a> Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603271643BIZWIRE_USPR_____20260327_BW190358) on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"个人用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDLqBlJC:1","article_id":"2622580804","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622580804","pubTimestamp":1774644199,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zivo Bioscience said a letter to shareholders from Chairman, President and CEO John B. Payne is available and outlines plans to deregister its securities with the SEC and stop public reporting.The letter cites public-company compliance costs and shareholder dilution from capital raises to fund reporting expenses as reasons for the decision.It states the company expects meaningful revenue from its AgTech product line through a distribution relationship in the coming months and says lower operating costs could support positive cash flow.Payne said animal health companies are conducting due diligence on Zivo’s non-antibiotic immune-modulating technology and that The University of Georgia plans to use Zivo’s product in avian influenza studies.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4183":"个人用品","ZIVO":"Zivo Bioscience, Inc."},"translate_title":"ZIVO Bioscience宣布提供股东信；公司计划撤销SEC注册并停止公开报告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZIVO":0.9},"content_text":"ZIVO Bioscience announces shareholder letter availability; company plans SEC deregistration and public reporting halt\n    \n\n\nZivo Bioscience said a letter to shareholders from Chairman, President and CEO John B. Payne is available and outlines plans to deregister its securities with the SEC and stop public reporting.\n        \n\n          The letter cites public-company compliance costs and shareholder dilution from capital raises to fund reporting expenses as reasons for the decision.\n        \n\n          It states the company expects meaningful revenue from its AgTech product line through a distribution relationship in the coming months and says lower operating costs could support positive cash flow.\n        \n\n          Payne said animal health companies are conducting due diligence on Zivo’s non-antibiotic immune-modulating technology and that The University of Georgia plans to use Zivo’s product in avian influenza studies.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zivo Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603271643BIZWIRE_USPR_____20260327_BW190358) on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622580804","isCrawlerRequest":true}